Exelixis (EXEL) Rated Equalweight by Barclays Amid Cancer Drug Outlook

Exelixis, Inc. (NASDAQ:EXEL) ranks among the most undervalued NASDAQ stocks to buy now. On September 17, Barclays began coverage of Exelixis, Inc. (NASDAQ:EXEL), rating it Equalweight and setting a price target of $40 on the company’s shares. The firm forecasts cabozantinib, Exelixis’ major value driver, will climb in the mid-single digits until its patent expires in 2029. Photo by National Cancer Institute on Unsplash Barclays predicts overall revenue for 2029 to be around 8% lower than consensus, owin ...